NCT07018375 Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lung Resection
| NCT ID | NCT07018375 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Tianjin Medical University General Hospital |
| Condition | Chronic Postsurgical Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 320 participants |
| Start Date | 2026-01-06 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 320 participants in total. It began in 2026-01-06 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective is to evaluate the impact of oliceridine versus sufentanil for perioperative analgesia on the incidence of chronic postsurgical pain (CPSP) with functional impact in patients undergoing video-assisted thoracoscopic surgery.
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years * ASA physical status I-III * BMI 18-35 kg/m² * Scheduled for unilateral video-assisted thoracoscopic surgery (VATS) lung resection, including wedge resection, segmentectomy, lobectomy, or radical resection for lung cancerresection for lung cancer * Preoperative Numeric Rating Scale (NRS) pain score of 0 * Ability to understand the study objectives and procedures, with voluntary informed consent obtained * Expected postoperative recovery in the general ward setting Exclusion Criteria: * History of chronic pain or long-term analgesic use prior to surgery * Previous ipsilateral thoracic surgery * Prior neoadjuvant radiotherapy or chemotherapy * Severe cardiovascular or cerebrovascular disease, or hepatic/renal dysfunction (ALT/AST \> 3 × upper limit of normal; eGFR \< 60 mL/min/1.73 m²) * Severe or unstable psychiatric disorders requiring psychoactive medication (e.g., schizophrenia, bipolar disorder), or cognitive impairment precluding reliable self-report * Other concurrent active malignancy or active infection * Known hypersensitivity to study medications (opioids, adjuvant analgesics, anesthetics, or antiemetics) * Pregnancy, lactation, or planned pregnancy during the study period * Participation in another interventional clinical trial within 3 months before enrolment * Any condition deemed unsuitable for study participation by the investigator
Contact & Investigator
Yang Jiao, Doctor
PRINCIPAL INVESTIGATOR
Tianjin Medical University General Hospital
Frequently Asked Questions
Who can join the NCT07018375 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Chronic Postsurgical Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07018375 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07018375 currently recruiting?
Yes, NCT07018375 is actively recruiting participants. Contact the research team at jiaoxiuxiu1987@163.com for enrollment information.
Where is the NCT07018375 trial being conducted?
This trial is being conducted at Baoding, China, Tangshan, China, Tianjin, China, Tianjin, China and 3 additional locations.
Who is sponsoring the NCT07018375 clinical trial?
NCT07018375 is sponsored by Tianjin Medical University General Hospital. The principal investigator is Yang Jiao, Doctor at Tianjin Medical University General Hospital. The trial plans to enroll 320 participants.